Amelia's journey with spinal muscular atrophy
By AmerisourceBergen
Spinal muscular atrophy (SMA) is a condition found in just 1 in 10,000 children born around the world and, if left untreated, more than 90% of patients may die or require permanent ventilation by the age of two.
At just six months old, Amelia was diagnosed with SMA and her family set out to obtain a one-time, potentially life-saving gene replacement therapy produced in the US.
The World Courier team harnessed our unique global network of local logistics and regulatory experts to make certain that the dose reached Amelia on time and in good condition.
To minimize the impact of routing disruptions due to the COVID-19 pandemic and safeguard against delays, we fitted a GPS tracker in addition to our existing advanced tracking capabilities. This allowed us to monitor the location of the thermal container from departure through to where Amelia was being treated.
Read the case study to discover why World Courier was approached by the leading biotech innovator behind this treatment for an urgent delivery to Chile.
